Axxcess Wealth Management LLC Takes $352,000 Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Axxcess Wealth Management LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the fourth quarter, HoldingsChannel reports. The fund acquired 5,342 shares of the company’s stock, valued at approximately $352,000.

Several other institutional investors also recently bought and sold shares of the business. Global Retirement Partners LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at about $39,000. Stratos Wealth Partners LTD. purchased a new stake in Invesco Biotechnology & Genome ETF during the fourth quarter valued at approximately $208,000. Creative Financial Designs Inc. ADV boosted its stake in Invesco Biotechnology & Genome ETF by 6.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 3,347 shares of the company’s stock valued at $220,000 after acquiring an additional 206 shares in the last quarter. Kestra Advisory Services LLC grew its holdings in Invesco Biotechnology & Genome ETF by 4.2% in the third quarter. Kestra Advisory Services LLC now owns 6,362 shares of the company’s stock worth $363,000 after purchasing an additional 254 shares during the last quarter. Finally, Penobscot Investment Management Company Inc. purchased a new position in Invesco Biotechnology & Genome ETF in the third quarter worth $562,000.

Invesco Biotechnology & Genome ETF Trading Down 0.6 %

Shares of PBE opened at $63.75 on Thursday. Invesco Biotechnology & Genome ETF has a 12 month low of $52.47 and a 12 month high of $67.76. The stock has a fifty day moving average price of $63.57 and a 200-day moving average price of $62.26. The firm has a market cap of $241.61 million, a PE ratio of 16.00 and a beta of 0.92.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.